跳至主要内容
临床试验/NCT00446329
NCT00446329终止4 期

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Papageorgiou General Hospital2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2006年7月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
15
试验地点
2
主要终点
Effects of cinacalcet on bone mineral density and bone histology in hemodialysis patients

研究概览

简要总结

The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day.

The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age older than 18 yrs
  • On hemodialysis for at least 3 months (thrice weekly)
  • iPTH >300pg/ml or histological evidence of secondary hyperparathyroidism
  • Calcium > 8.1 mg/dl

排除标准

  • Unstable clinical condition

结局指标

主要结局

Effects of cinacalcet on bone mineral density and bone histology in hemodialysis patients

时间窗: one year period

次要结局

未报告次要终点

研究者

发起方
Papageorgiou General Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Efstathios Mitsopoulos

Nephrologist

Papageorgiou General Hospital

研究点 (2)

Loading locations...

相似试验